New Jersey Legislature Works to Increase Penalties for Drug Counterfeiters

In June, the New Jersey Assembly passed A-5037, a bill that increases penalties for those who create, distribute or administer counterfeit, adulterated or misbranded medical drugs and devices. The legislation, which has been sent to the New Jersey Senate’s Budget and Appropriations Committee, would make the sale of more than 100 units of fake medicine punishable by a sentence of five to ten years, a fine of up to $150,000, or both.

[...]

“Canada cannot act as a drugstore for the United States,” says academic

In this editorial, which was published by the Fraser Institute on June 13, 2019, economist Dr. Kristina Acri argues against importation, concluding: “Diverting drugs meant for Canadian patients to the U.S. through state importation schemes will create shortages for Canadian patients and increase pressure on potentially unscrupulous suppliers to source drugs from wherever they can, opening the door to counterfeiters.”

[...]